Strong willingness of traditional Chinese medicine to enter medical insurance: 96% success rate of negotiation

In 2019, the negotiation of medical insurance came to an end Of the 19 Chinese patent medicines to be negotiated, 18 were successfully negotiated and successfully entered the national medical insurance In addition, five Chinese patent medicines successfully negotiated in 2017 were all shortlisted in this round of renewal negotiation, making the number of Chinese patent medicines successfully negotiated in 2019 reach 23, and the success rate of this negotiation reached an amazing 96% Chinese patent medicine varieties successfully negotiated in 2019 Note: 1-18 is the successful traditional Chinese medicine variety in the first negotiation; 19-23 is the successful traditional Chinese medicine variety in the renewal negotiation The Chinese patent medicines involved in the renewal negotiations include ginkgolide glucosamine injection, ginkgolide injection, compound Huangdai tablet, astragalus polysaccharide for injection and Shenyi capsule These five renewal negotiation varieties are willing to renew at a reduced price again, which is inseparable from the effect of rapid and large-scale after joining the medical insurance The volume of ginkgolide meglumine injection increased rapidly after entering the medical insurance According to Kangyuan pharmaceutical, the manufacturer, the operating revenue of ginkgolide meglumine injection in 2016 was 75.8466 million yuan, accounting for 2.53% of the total operating revenue of the company In 2017, Kangyuan pharmaceutical's Ginkgo diterpenoid lactone and meglumine injection entered the medical insurance category B catalogue through national negotiation, with the price reduced by 50% to 316 yuan each from the previous 620 yuan According to the company's annual report in 2018, the sales volume of Ginkgo diterpenoid lactone in 2018 was 1577500 boxes, with an increase of 66.39% The sales volume was about 500 million yuan, accounting for more than 10% of the company's sales volume for the first time Although the price reduction is relatively large, due to the huge market scale and the small base of the company, and the implementation of reimbursement within more than one year of medical insurance negotiation, the volume of ginkgolide is growing rapidly The manufacturer of ginkgolide injection is Chengdu Baiyu Pharmaceutical Co., Ltd According to the company, since the ginkgolide injection entered the national medical insurance catalog in 2017, the market demand is increasing sharply In the first quarter of 2019 alone, the demand has reached 2 million, more than 30% of the annual sales in 2017 In March this year, the construction of "China's largest ginkgolide injection production base" was officially started According to the company, the total investment of the project is 3.3 billion yuan, and the project is expected to be completed and put into operation in June 2019 After being put into production, it is expected to achieve annual output of several billion pieces, which has more than doubled by 10 times based on the current annual output of tens of millions pieces In addition to meeting the domestic market demand, it will also be exported to Europe, the United States and other countries, and it is expected that the annual sales will exceed 6 billion in the future Compound Huangdai tablet was used in the treatment of acute promyelocytic leukemia In 2017, it was the first time to enter the medical insurance through medical insurance negotiation After entering the insurance, the quantity is obvious The manufacturer of compound Huangdai tablet is Tianchang Yifan Pharmaceutical Co., Ltd., which is a subsidiary of Yifan pharmaceutical In May 2018, Yifan pharmaceutical once revealed that since the compound Huangdai tablet was included in the national medical insurance negotiation catalog, it has provided a new growth point for the company's business performance improvement, and its sales volume in the first quarter of 2018 increased by more than 60% compared with the same period last year The success rate of the negotiation on traditional Chinese medicine varieties is so high, which shows that the willingness of traditional Chinese medicine to enter the medical insurance is extremely strong, and also reflects some changes or characteristics of the domestic pharmaceutical industry In recent years, the pace of development of innovative Chinese medicine has slowed down obviously, and the increment of market supply side is very small Since 2016, the State Food and drug administration, which has accelerated the review and approval, has approved about 130 new drugs, but only four of them are traditional Chinese medicine Therefore, we can also see from the above table that nearly 70% (12) of the 18 traditional Chinese medicines that have been successfully negotiated (excluding the renewal negotiation) were approved for listing before 2010, so this negotiation of traditional Chinese medicine type medical insurance mainly solved the problem of old varieties entering medical insurance In addition, the national level is still vigorously encouraging the innovation of traditional Chinese medicine and developing supporting policies for the research and development of traditional Chinese medicine However, in the marketing end, the market environment or voice of traditional Chinese medicine is not friendly in recent years The auxiliary drug catalogue and key clinical drug monitoring catalogue participated by the health and Health Commission and the medical insurance bureau have severely hit the use of traditional Chinese medicine injection in hospitals, resulting in a serious decline in the sales revenue of many large varieties of traditional Chinese medicine In addition, some national policy documents pointed out that the prescription of Chinese patent medicine and the prescription of Chinese herbal pieces should be issued by qualified doctors, which led to the discussion of "can western medicine prescribe Chinese herbal medicine" and the anxiety of Chinese herbal medicine enterprises.